143127-80-4

Basic information

• Product Name: Benzene, 1-(bromomethyl)-4-[2-(2-methoxyethoxy)ethoxy]-
• CAS NO: 143127-80-4
• Molecular Formula: C12H17BrO3
• Molecular Weight: 289.169
• Mol File: 143127-80-4.mol

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(bromomethyl)-4-[2-(2-methoxyethoxy)ethoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(bromomethyl)-4-[2-(2-methoxyethoxy)ethoxy]-(143127-80-4)
• EPA Substance Registry System: Benzene, 1-(bromomethyl)-4-[2-(2-methoxyethoxy)ethoxy]-(143127-80-4)

Safety Data

• Hazardous Substances Data: 143127-80-4(Hazardous Substances Data)

Upstream product

• 54149-17-6 2-bromoethyl 2-methoxyethyl ether 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 392711-13-6 (4-(2-(2-methoxyethoxy)ethoxy)phenyl)methanol 
• 558-13-4 carbon tetrabromide 
• 623-05-2 (4-hydroxyphenyl)methanol 

Relevant articles and documents

Polyviologen dendrimers as hosts and charge-storing devices

Two dendrimers were designed and synthesized that contain a 1,3,5-trisubstituted benzenoid core and incorporate 9 and 21 viologen (4,4′-bipyridinium) units in their branches in addition to hydrophilic (aryloxy) terminal groups. For comparison purposes, model compounds containing one and two viologen units were also studied. These polycationic dendrimers form strong host-guest complexes with the dianionic form of the red dye eosin in dilute CH2Cl2 solutions. Titration experiments, based on fluorescence measurements, showed that each viologen unit in the dendritic structures becomes associated with an eosin dianion. Electrochemical (in MeCN) and photosensitization (in CH2Cl2) experiments revealed that only a fraction of the viologen units present in the dendritic structures can be reduced. This fraction corresponds to the number of viologen units present in the outer shells of the dendrimers. The reasons for incomplete charge pooling are discussed. Comparison with the behavior of polyviologen dendrimers that are terminated with bulky tetraarylmethane groups and were studied previously enabled the role played by the terminal groups in the redox and hosting properties to be elucidated.

HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS

This invention relates to novel heteroaryl substituted pyrazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients or therapeutic measures.

HIV protease inhibitors having polyether substituents

[From equivalent EP0487270A2] Polyether derivatives of the form, A-G-B-B-J ψ wherein G is a dipeptide isostere substituted with a polyether, B an amino acid or analog thereof, and J a small terminal group are described. These compounds are useful in the inhibition of DIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.ψ